R&G PharmaStudies Co., Ltd. (SHE:301333)
China · Delayed Price · Currency is CNY 49.92
+0.87 (1.77%)
At close: Jun 23, 2026
R&G PharmaStudies Market Cap
R&G PharmaStudies has a market cap or net worth of 4.71 billion as of June 23, 2026. Its market cap has increased by 4.92% in one year.
Market Cap
4.71B
Enterprise Value
3.00B
Revenue
896.26M
Ranking
n/a
PE Ratio
35.00
Stock Price
49.92
Market Cap Chart
Since August 2, 2022, R&G PharmaStudies's market cap has decreased from 5.40B to 4.71B, a decrease of -12.82%. That is a compound annual growth rate of -3.46%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 23, 2026 | 4.71B | -16.89% |
| Dec 31, 2025 | 5.67B | 19.12% |
| Dec 31, 2024 | 4.76B | -23.17% |
| Dec 29, 2023 | 6.19B | 25.30% |
| Dec 30, 2022 | 4.94B | -8.52% |
| Aug 2, 2022 | 5.40B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Anhui Huaheng Biotechnology | 5.24B |
| Hangzhou Biotest Biotech | 5.18B |
| Novogene | 5.10B |
| Jiangsu Aidea Pharmaceutical Group | 5.04B |
| Shenzhen Weiguang Biological Products | 4.91B |
| Shanghai Serum Bio-Technology | 4.86B |
| PharmaResources (Shanghai) | 4.84B |
| Zhejiang Wecome Pharmaceutical Company | 4.79B |